“Combining the 31-gene expression profile test for cutaneous melanoma with the American Joint Committee on Cancer staging identifies the highest-risk patients with stage I-II disease”, J of Skin, vol. 7, no. 4, p. s223, Jul. 2023, doi: 10.25251/skin.7.supp.223.